Norrie disease (ND) is a severe form of congenital blindness accompanied by mental retardation and/or deafness in at least one third of the patients. This article summarizes advances in the molecular genetic analysis of this disease during the last 13 years, including mapping and cloning of the human gene and the generation and characterization of a mouse model. Genetic linkage studies and physical mapping strategies have assigned the ND locus to the proximal short arm of the human X chromosome. The identification of chromosomal rearrangements in several patients, such as microdeletions, enabled the isolation of the ND gene by a positional cloning approach. Numerous point mutations in this gene have been identified in three distinct clinical entities: (1) ND, (2) familial and sporadic exudative vitreoretinopathy, and (3) retinopathy of prematurity. The gene encodes a relatively small protein, consisting of 133 amino acids. The function of the gene product is yet unknown, although homologies with known proteins and molecular modelling data suggest a role in the regulation of cell interaction or differentiation processes. A mouse model has been generated to shed more light on early pathogenic events involved in ND and allelic disorders. The mouse homologous protein is highly identical (94%) to the human polypeptide. The gene is expressed in the neuronal layers of the mouse retina, the cerebellum and olfactory epithelium. Mutant mice show snowflake-like opacities within the vitreous, dysgenesis of the ganglion cell layer and occasionally degeneration of photoreceptor cells. The mouse phenotype does not include phthisis bulbi and, overall, resembles a mild form of ND. Electrophysiological studies revealed a severely altered electroretinogram b-wave. These results suggest a primary defect in the inner neuronal layers of the retina. Defects in the vitreous and photoreceptor cell layer are most likely secondary effects. Further histological, functional and molecular studies of the mouse model are needed to provide additional information on disease associated pathways.

Keywords:
Norrie disease, Vitreoretinopathy, Retinopathy of prematurity, Gene mutation, Mouse model
1.
Apple, D.J., G.A. Fishman, M.F. Goldberg (1974) Ocular histopathology of Norrie’s disease. Am J Ophthalmol 78: 196–203.
2.
Berger, W., A. Meindl, T.J.R. van de Pol, F.P.M. Cremers, H.H. Ropers, C. Dörner, A. Monaco, A.A.B. Bergen, R. Lebo, M. Warburg, L. Zergollern, B. Lorenz, A. Gal, E.M. Bleeker-Wagemakers, T. Meitinger (1992a) Isolation of a candidate gene for Norrie disease by positional cloning. Nat Genet 1: 199–203.
3.
Berger, W., D. van de Pol, M. Warburg, A. Gal, L. Bleeker-Wagemakers, H. de Silva, A. Meindl, T. Meitinger, F. Cremers, H.H. Ropers (1992b) Mutations in the candidate gene for Norrie disease. Hum Mol Genet 1: 461–465.
4.
Berger, W., D. van de Pol, D. Bächner, F. Oerlemans, H. Winkens, H. Hameister, B. Wieringa, W. Hendriks, H.-H. Ropers (1996) An animal model for Norrie disease (ND): Gene targeting of the mouse ND gene. Hum Mol Genet 5: 51–59.
5.
Chen, Z.-Y., R.W. Hendriks, M.A. Jobling, J.F. Powell, X.O. Breakefield, K.B. Sims, I.W. Craig (1992) Isolation and characterization of a candidate gene for Norrie disease. Nat Genet 1: 204–208.
6.
Chen, Z.-Y., E.M. Battinelli, A. Fielder, S. Bundey, K. Sims, X.O. Breakfield, I.W. Craig (1993a) A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy. Nat Genet 5: 180–183.
7.
Chen, Z.-Y., E.M. Battinelli, R.W. Hendriks, J.F. Powell, H. Middleton-Price, K.B. Sims, X.O. Breakefield, I.W. Craig (1993b) Norrie disease gene: Characterization of deletions and possible function. Genomics 16: 533–535.
8.
Chen, Z.-Y., E.M. Battinelli, G. Woodruff, I. Young, X.O. Breakefield, I.W. Craig (1993c) Characterization of a mutation within the NDP gene in a family with a manifesting female carrier. Hum Mol Genet 2: 1727–1729.
9.
de la Chapelle, A., E.-M. Sankila, M. Lindlöf, P. Aula, R. Norio (1985) Norrie disease caused by a gene deletion allowing carrier detection and prenatal diagnosis. Clin Genet 28: 317–320.
10.
Donnai, D., R.C. Mountford, A.P. Read (1988) Norrie disease resulting from a gene deletion: Clinical features and DNA studies. J Med Genet 25: 73–78.
11.
Fuchs, S., S.Y. Xu, M. Caballero, M. Salcedo, O.A. La, H. Wedemann, A. Gal (1994) A missense point mutation (Leu13Arg) of the Norrie disease gene in a large Cuban kindred with Norrie disease. Hum Mol Genet 3: 655–656.
12.
Fuchs, S., D. van de Pol, U. Beudt, U. Kellner, F. Meire, W. Berger, A. Gal (1996) Three novel and two recurrent mutations of the Norrie disease gene in patients with Norrie syndrome. Hum Mutat 8: 85–88.
13.
Fuentes, J.-J., V. Volpini, F. Fernández-Toral, E. Coto, X. Estivill (1993) Identification of two new missense mutations (K58N and R121Q) in the Norrie disease (ND) gene in two Spanish families. Hum Mol Genet 2: 1953–1955.
14.
Gal, A., C. Stolzenberger, T. Wienker, P. Wieacker, H.H. Ropers, U. Friedrich, L. Bleeker-Wagemakers, P. Pearson, M. Warburg (1985) Norrie’s disease: Close linkage with genetic markers from the proximal short arm of the X chromosome. Clin Genet 27: 282–283.
15.
Gal, A., B. Wieringa, D.F.C.M. Smeets, L. Bleeker-Wagemakers, H.H. Ropers (1986) Submicroscopic interstitial deletion of the X chromosome explains a complex genetic syndrome dominated by Norrie disease. Cytogenet Cell Genet 42: 219–224.
16.
Gal, A., A. Veske, G. Jojart, B. Grammatico, B. Huber, S. Gu, G. del Porto, K. Senyi (1996) Norrie-Warburg syndrome: Two novel mutations in patients with classical clinical phenotype. Acta Ophthalmol Scand 74: 13–16.
17.
Isashiki, Y., N. Ohba, T. Yanagita, N. Hokita, N. Doi, M. Nakagawa, M. Ozawa, N. Kuroda (1995a) Novel mutation at the initiation codon in the Norrie disease gene in two Japanese families. Hum Genet 95: 105–108.
18.
Isashiki, Y., N. Ohba, T. Yanagita, N. Hokita, Y. Hotta, M. Hayakawa, K. Fujiki, U. Tanabe (1995b) Mutations in the Norrie disease gene – A new mutation in a Japanese family. Br J Ophthalmol 79: 703–704.
19.
Johnson, K., H.A. Mintz-Hittner, Y.P. Conley, R.E. Ferrell (1996) X-linked exudative vitreoretinopathy caused by an arginine to leucine substitution (R121L) in the Norrie disease protein. Clin Genet 50: 113–115.
20.
Joos, K.M., A.E. Kimura, K. Vandenburgh, J.A. Bartley, E.M. Stone (1994) Ocular findings associated with a Cys39Arg mutation in the Norrie disease gene. Arch Ophthalmol 112: 1574–1579.
21.
Kellner, U., S. Fuchs, N. Bornfeld, M.H. Foerster, A. Gal (1996) Ocular phenotypes associated with two mutations (R121W, C126X) in the Norrie disease gene. Ophthalmic Genet 17: 67–74.
22.
Lindsay, S., D.L. Thiselton, J.B. Bateman, J.T. Ngo, R.S. Sparkes, M. Coleman, K.E. Davies, S.S. Bhattacharya (1992) Localisation of the gene for Norrie disease to between DXS7 and DXS426 on Xp. Hum Genet 88: 349–350.
23.
Meindl, A., W. Berger, T. Meitinger, D. van de Pol, H. Achatz, C. Dörner, M. Haasemann, H. Hellebrand, A. Gal, F. Cremers, H.H. Ropers (1992) Norrie disease is caused by mutations in an extracellular protein resembling C-terminal globular domain of mucins. Nat Genet 2: 139–143.
24.
Meindl, A., B. Lorenz, H. Achatz, H. Hellebrand, P. Schmitz-Valckenberg, T. Meitinger (1995) Missense mutations in the NDP gene in patients with a less severe course of Norrie disease. Hum Mol Genet 4: 489–490.
25.
Meitinger, T., A. Meindl, P. Bork, B. Rost, C. Sander, M. Haasemann, J. Murken (1993) Molecular modelling of the Norrie disease protein predicts a cystine knot growth factor tertiary structure. Nat Genet 5: 376–380.
26.
Mintz-Hittner, H.A., R.E. Ferrel, K.B. Sims, K.M. Fernandez, B.S. Gemmell, D.R. Satriano, J. Caster, F.L. Kretzer (1996) Peripheral retinopathy in offspring of carriers of Norrie disease gene mutations. Possible transplacental effect of abnormal Norrin. Ophthalmology 103: 2128–2134.
27.
Norrie, G. (1927) Causes of blindness in children. Acta Ophthalmol 5: 357–386.
28.
Norrie, G. (1933) Nogle blindhedsaarsager: en oversigt. Hospitalstidende 76: 141–147.
29.
Ohba, N., T. Yamashita (1986) Primary vitreoretinal dysplasia resembling Norrie disease in a female: Association with X/autosome chromosomal translocation. Br J Ophthalmol 70: 64–71.
30.
Parsons, M.A., D. Curtis, C.E. Blank, H.N. Hughes, C.E. McCartney (1992) The ocular pathology of Norrie disease in a fetus of 11 weeks gestational age. Graefes Arch Clin Exp Ophthalmol 230: 248–251.
31.
Pettenati, M.J., P.N. Rao, J.R.G. Weaver, I.T. Thomas, M.R. McMahan (1993) Inversion (X)(p11.4q22) associated with Norrie disease in a four generation family. Am J Med Genet 45: 577–580.
32.
Rehm, H.L., G.A. Gutiérrez-Espeleta, R. Garcia, G. Jiménez, U. Khetarpal, J.M. Priest, K.B. Sims, B.J.B. Keats, C.C. Morton (1997) Norrie disease gene mutation in a large Costa Rican kindred with a novel phenotype including venous insufficiency. Hum Mutat 9: 402–408.
33.
Ruether, K., D. van de Pol, G. Jaissle, W. Berger, R.P. Tornow, E. Zrenner (1997) Retinoschisis-like alterations in the mouse eye due to gene targeting of the Norrie disease (ND) gene. Invest Ophthalmol Vis Sci 38: 710–718.
34.
Schroeder, B., L. Hesse, W. Brück, A. Gal (1997) Histopathological and immunohistochemical findings associated with a null mutation in the Norrie disease gene. Ophthalmic Genet 18: 71–77.
35.
Schuback, D.E., Z.-Y. Chen, I.W. Craig, X.O. Breakefield, K.B. Sims (1995) Mutations in the Norrie disease gene. Hum Mutat 5: 285–292.
36.
Shastry, B.S., J.F. Hejtmancik, D.A. Plager, M.K. Hartzer, M.T. Trese (1995) Linkage and candidate gene analysis of X-linked familial exudative vitreoretinopathy. Genomics 27: 341–344.
37.
Shastry, B.S., J.F. Hejtmancik, M.T. Trese (1997a) Identification of novel missense mutations in the Norrie disease gene associated with one X-linked and four sporadic cases of familial exudative vitreoretinopathy. Hum Mutat 9: 396–401.
38.
Shastry, B.S., S.D. Pendergast, M.K. Hartzer, X. Liu, M.T. Trese (1997b) Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. Arch Ophthalmol 115: 651–655.
39.
Sims, K.B., A. de la Chapelle, R. Norio, E.-M. Sankila, Y.-P.P. Hsu, W.B. Rinehart, T.J. Correy, L. Ozelius, J.F. Powell, G. Bruns, J.F. Gusella, D.L. Murphy, X.O. Breakefield (1989) Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron 2: 1069–1076.
40.
Sims, K.B., R.V. Lebo, G. Benson, C. Shalish, D. Schuback, Z.-Y. Chen, G. Bruns, I.W. Craig, M.S. Golbus, X.O. Breakefield (1992) The Norrie disease gene maps to a 150 kbp region on chromosome Xp11.3. Hum Mol Genet 1: 83–89.
41.
Sims, K.B., A.R. Irvine, W.V. Good (1997) Norrie disease in a family with a manifesting female carrier. Arch Ophthalmol 115: 517–519.
42.
Strasberg, P., H.A. Liede, T. Stein, I. Warren, J. Sutherland, P.N. Ray (1995) A novel mutation in the Norrie disease gene predicted to disrupt the cystine knot growth factor motif. Hum Mol Genet 4: 2179–2180.
43.
Torrente I., M. Mangino, M. Gennarelli, G. Novelli, A. Giannotti, A. Vadalà, B. Dallapiccola (1997) Two new missense mutations (A105T and C110G) in the Norrin gene in two Italian families with Norrie disease and familial exudative vitreoretinopathy. Am J Med Genet 72: 242–244.
44.
Walker, J.L., J. Dixon, C.R. Fenton, J. Hungerford, S.A. Lynch, S.A. Stenhouses, A. Christian, I.W. Craig (1997) Two new mutations in exon 3 of the NDP gene: S73X and S101F associated with severe and less severe ocular phenotype, respectively. Hum Mutat 9: 53–56.
45.
Warburg, M. (1966) Norrie’s disease. A congenital progressive oculo-acoustico-cerebral degeneration. Acta Ophthalmol 89(suppl): 1–147.
46.
Warburg, M. (1968) Norrie’s disease. J Ment Defic Res 12: 247–251.
48.
Zhu, D., S.E. Antonarakis, B.J. Schmeckpeper, P.J. Diergaarde, A.E. Greb, I.H. Maumenee (1989) Microdeletion in the X-chromosome and prenatal diagnosis in a family with Norrie disease. Am J Med Genet 33: 485–488.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.